EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudieOpen Access · CC BY-NC 4.0

Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register

Martin Schaefer, Alina Purschke, Vera Zietemann, Tatjana Rudi, Yvette Meissner, Adrian Richter, Sylvia Berger, Karin Rockwitz, Klaus Krüger, Karl Matthias Schneider, Anne C Regierer, Anja Strangfeld

Annals of the Rheumatic Diseases · 2025-11 · 84 (11) · 1779-1790

DOI: 10.1016/j.ard.2025.05.014 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Annals of the Rheumatic Diseases, 2025-11. Verfasst von Martin Schaefer und 11 weiteren Autor:innen. Beteiligte Einrichtung: Programme Area Epidemiology and Health Services Research, German Rheumatology Research Center, Berlin, Germany. Electronic address: martin.schaefer@d…. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Janus Kinase Inhibitors, Neoplasms, Antirheumatic Agents. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: UCB, Lilly Deutschland GmbH, Pfizer Pharma GmbH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidJanus Kinase InhibitorsNeoplasmsAntirheumatic AgentsBiological ProductsHumansMaleFemaleGermanyMiddle AgedIncidenceRegistriesAgedAzetidinesAdultSulfonamidesPyrimidinesPurinesPiperidinesPyrazoles

Substanzen

Janus Kinase InhibitorsAntirheumatic AgentstofacitinibbaricitinibAzetidinesBiological ProductsSulfonamidesPyrimidinesPurinesPiperidines

Autor:innen und Institutionen

  • Programme Area Epidemiology and Health Services Research, German Rheumatology Research Center, Berlin, Germany. Electronic address: martin.schaefer@drfz.de.
  • Programme Area Epidemiology and Health Services Research, German Rheumatology Research Center, Berlin, Germany.
  • Programme Area Epidemiology and Health Services Research, German Rheumatology Research Center, Berlin, Germany; Department SHIP-KEF, Institute for Community Medicine, University Medical Center Greifswald, Greifswald, Ge…
  • Rheumatological Practice, Naunhof, Germany.
  • Rheumatological Practice, Goslar, Germany.
  • Rheumatological Practice Center, Munich, Germany.

Förderung

  • UCB
  • Lilly Deutschland GmbH
  • Pfizer Pharma GmbH
  • AbbVie Deutschland GmbH & Co KG
  • Bristol-Myers Squibb GmbH & Co. KGaA
  • Sanofi-Aventis Deutschland GmbH
  • Roche
  • Samsung Bioepis Co., Ltd.

Zitieren

APA

Schaefer, M., Purschke, A., Zietemann, V., Rudi, T., Meissner, Y., Richter, A., Berger, S., Rockwitz, K., Krüger, K., Schneider, K. M., Regierer, A. C., & Strangfeld, A. (2025). Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register. Annals of the Rheumatic Diseases, 84(11), 1779-1790. https://doi.org/10.1016/j.ard.2025.05.014

Vancouver

Schaefer M, Purschke A, Zietemann V, Rudi T, Meissner Y, Richter A, et al. Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register. Annals of the Rheumatic Diseases. 2025;84(11):1779-1790. doi:10.1016/j.ard.2025.05.014

BibTeX
@article{Schaefer2025,
  author = {Schaefer, Martin and Purschke, Alina and Zietemann, Vera and Rudi, Tatjana and Meissner, Yvette and Richter, Adrian and Berger, Sylvia and Rockwitz, Karin and Krüger, Klaus and Schneider, Karl Matthias and Regierer, Anne C and Strangfeld, Anja},
  title = {Comparative risk of incident malignancies in rheumatoid arthritis patients treated with Janus kinase inhibitors or bDMARDs: observational data from the German RABBIT register},
  journal = {Annals of the Rheumatic Diseases},
  year = {2025},
  volume = {84},
  number = {11},
  pages = {1779--1790},
  doi = {10.1016/j.ard.2025.05.014}
}
Kostenlos starten →